We are live on ! Find out more
EDIT icon

Editas Medicine

257 hedge funds and large institutions have $862M invested in Editas Medicine in 2022 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 82 increasing their positions, 67 reducing their positions, and 75 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 67

9.18% less ownership

Funds ownership: 75.41% → 66.23% (-9.2%)

16% less funds holding

Funds holding: 307 → 257 (-50)

20% less call options, than puts

Call options by funds: $31.2M | Put options by funds: $38.8M

53% less capital inflows, than outflows

Capital inflows: $131M | Capital outflows: $280M

60% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 75

Holders
257
Holders Change
-50
Holders Change %
-16.29%
% of All Funds
4.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
82
Reduced
67
Closed
75
Calls
$31.2​M
Puts
$38.8​M
Net Calls
-⁠$7.64​M
Net Calls Change
+$24.6​M

EDIT Hedge Fund Activity: Q1 2022 in Review

257 of the 6,366 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2022, worth a combined $862M — down 37% from $1.37B a quarter earlier.

Sellers outnumbered buyers: 75 funds closed out of EDIT and 30 opened new positions — a net loss of 45 holders — while 67 trimmed existing stakes and 82 added.

The largest buyer was State Street, adding an estimated $41M. The largest seller was ARK Investment Management, cutting an estimated $63.6M.

  • 257 institutional investors held Editas Medicine (EDIT) as of Q1 2022, down from 307 in Q4 2021.
  • Funds reported $862M of Editas Medicine stock for Q1 2022, down 37% quarter-over-quarter.
  • 30 funds opened new Editas Medicine positions in Q1 2022 and 75 closed out, a net change of -45 holders.
  • The largest Editas Medicine buyer in Q1 2022 was State Street, an estimated $41M added.
  • The largest Editas Medicine seller in Q1 2022 was ARK Investment Management, an estimated $63.6M sold.

Based on aggregated 13F filings for Q1 2022.